Literature DB >> 26893157

Prucalopride exerts neuroprotection in human enteric neurons.

Francesca Bianco1, Elena Bonora2, Dipa Natarajan3, Manuela Vargiolu4, Nikhil Thapar4, Francesco Torresan5, Fiorella Giancola1, Elisa Boschetti2, Umberto Volta2, Franco Bazzoli2, Maurizio Mazzoni6, Marco Seri2, Paolo Clavenzani6, Vincenzo Stanghellini2, Catia Sternini7, Roberto De Giorgio8.   

Abstract

Serotonin (5-hydroxytryptamine, 5-HT) and its transporters and receptors are involved in a wide array of digestive functions. In particular, 5-HT4 receptors are known to mediate intestinal peristalsis and recent data in experimental animals have shown their role in neuronal maintenance and neurogenesis. This study has been designed to test whether prucalopride, a well-known full 5-HT4 agonist, exerts protective effects on neurons, including enteric neurons, exposed to oxidative stress challenge. Sulforhodamine B assay was used to determine the survival of SH-SY5Y cells, human enteric neurospheres, and ex vivo submucosal neurons following H2O2 exposure in the presence or absence of prucalopride (1 nM). Specificity of 5-HT4-mediated neuroprotection was established by experiments performed in the presence of GR113808, a 5-HT4 antagonist. Prucalopride exhibited a significant neuroprotective effect. SH-SY5Y cells pretreated with prucalopride were protected from the injury elicited by H2O2 as shown by increased survival (73.5 ± 0.1% of neuronal survival vs. 33.3 ± 0.1%, respectively; P < 0.0001) and a significant reduction of proapoptotic caspase-3 and caspase-9 activation in all neurons tested. The protective effect of prucalopride was reversed by the specific 5-HT4 antagonist GR113808. Prucalopride promotes a significant neuroprotection against oxidative-mediated proapoptotic mechanisms. Our data pave the way for novel therapeutic implications of full 5-HT4 agonists in gut dysmotility characterized by neuronal degeneration, which go beyond the well-known enterokinetic effect.
Copyright © 2016 the American Physiological Society.

Entities:  

Keywords:  5-HT4 full agonist; enterokinetic drug; prucalopride; serotonin

Mesh:

Substances:

Year:  2016        PMID: 26893157      PMCID: PMC5243219          DOI: 10.1152/ajpgi.00036.2016

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  27 in total

Review 1.  Cell death: critical control points.

Authors:  Nika N Danial; Stanley J Korsmeyer
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

2.  Identification of neurons that express 5-hydroxytryptamine4 receptors in intestine.

Authors:  Daniel P Poole; Bo Xu; Shir Lin Koh; Billie Hunne; Ian M Coupar; Helen R Irving; Katsuhiro Shinjo; John B Furness
Journal:  Cell Tissue Res       Date:  2006-04-21       Impact factor: 5.249

Review 3.  Serotonin and neuroprotection in functional bowel disorders.

Authors:  M D Gershon; M-T Liu
Journal:  Neurogastroenterol Motil       Date:  2007-08       Impact factor: 3.598

Review 4.  Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets.

Authors:  Gary M Mawe; Jill M Hoffman
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-06-25       Impact factor: 46.802

5.  Involvement of activation of the Nrf2/ARE pathway in protection against 6-OHDA-induced SH-SY5Y cell death by α-iso-cubebenol.

Authors:  Sun Young Park; Do Yeon Kim; Jong-Koo Kang; Geuntae Park; Young-Whan Choi
Journal:  Neurotoxicology       Date:  2014-07-02       Impact factor: 4.294

6.  Anti-HuD-induced neuronal apoptosis underlying paraneoplastic gut dysmotility.

Authors:  Roberto De Giorgio; Monica Bovara; Giovanni Barbara; Marco Canossa; Giovanni Sarnelli; Fabrizio De Ponti; Vincenzo Stanghellini; Marcello Tonini; Silvia Cappello; Eleonora Pagnotta; Eduardo Nobile-Orazio; Roberto Corinaldesi
Journal:  Gastroenterology       Date:  2003-07       Impact factor: 22.682

7.  Routine colonic biopsies as a new tool to study the enteric nervous system in living patients.

Authors:  T Lebouvier; E Coron; T Chaumette; S Paillusson; S Bruley des Varannes; M Neunlist; P Derkinderen
Journal:  Neurogastroenterol Motil       Date:  2009-07-21       Impact factor: 3.598

8.  GR113808: a novel, selective antagonist with high affinity at the 5-HT4 receptor.

Authors:  J D Gale; C J Grossman; J W Whitehead; A W Oxford; K T Bunce; P P Humphrey
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

Review 9.  The 5-hydroxytryptamine 4 Receptor Agonist-induced Actions and Enteric Neurogenesis in the Gut.

Authors:  Miyako Takaki; Kei Goto; Isao Kawahara
Journal:  J Neurogastroenterol Motil       Date:  2013-12-30       Impact factor: 4.924

10.  Prucalopride improves bowel function and colonic transit time in patients with chronic constipation: an integrated analysis.

Authors:  Anton Emmanuel; Marina Cools; Lieve Vandeplassche; René Kerstens
Journal:  Am J Gastroenterol       Date:  2014-04-15       Impact factor: 10.864

View more
  12 in total

Review 1.  An update on prucalopride in the treatment of chronic constipation.

Authors:  Anam Omer; Eamonn M M Quigley
Journal:  Therap Adv Gastroenterol       Date:  2017-10-16       Impact factor: 4.409

2.  5-HT4-mediated neuroprotection: a new therapeutic modality on the way?

Authors:  Michael D Gershon
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-03-24       Impact factor: 4.052

Review 3.  Diabetes and the Small Intestine.

Authors:  Jonathan Gotfried; Stephen Priest; Ron Schey
Journal:  Curr Treat Options Gastroenterol       Date:  2017-12

Review 4.  Non-conventional features of peripheral serotonin signalling - the gut and beyond.

Authors:  Stephanie N Spohn; Gary M Mawe
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-05-10       Impact factor: 46.802

5.  Prophylactic efficacy of 5-HT4R agonists against stress.

Authors:  Briana K Chen; Indira Mendez-David; Victor M Luna; Charlène Faye; Alain M Gardier; Denis J David; Christine A Denny
Journal:  Neuropsychopharmacology       Date:  2019-10-10       Impact factor: 7.853

Review 6.  Novel aspects of enteric serotonergic signaling in health and brain-gut disease.

Authors:  Andrew Del Colle; Narek Israelyan; Kara Gross Margolis
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-11-04       Impact factor: 4.052

Review 7.  Prucalopride: For functional constipation only?

Authors:  M Bellini; D Gambaccini; G Bassotti
Journal:  Tech Coloproctol       Date:  2016-05-12       Impact factor: 3.781

Review 8.  Enteric Neuronal Regulation of Intestinal Inflammation.

Authors:  Kara Gross Margolis; Michael D Gershon
Journal:  Trends Neurosci       Date:  2016-07-20       Impact factor: 13.837

Review 9.  Prokinetics in the Management of Functional Gastrointestinal Disorders.

Authors:  Eamonn M M Quigley
Journal:  Curr Gastroenterol Rep       Date:  2017-09-08

10.  Prucalopride inhibits the glioma cells proliferation and induces autophagy via AKT-mTOR pathway.

Authors:  Hong Qiao; Yong-Bo Wang; Yu-Mei Gao; Li-Li Bi
Journal:  BMC Neurol       Date:  2018-06-04       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.